NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
Current Value
$1.271 Year Return
Current Value
$1.271 Year Return
Market Cap
$18.36M
P/E Ratio
-1.69
1Y Stock Return
17.97%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.8
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GRAL | 35.27% | $508.58M | -3.65% | 0.00% |
ZNTL | 24.64% | $226.62M | -69.48% | 0.00% |
CRCT | 24.36% | $1.11B | -19.79% | 1.94% |
NEWT | 23.64% | $370.38M | +8.39% | 5.33% |
SLQT | 22.47% | $447.63M | +103.91% | 0.00% |
CODX | 21.98% | $33.85M | -15.87% | 0.00% |
VRA | 21.57% | $148.75M | -31.02% | 0.00% |
FUN | 21.43% | $4.54B | -17.47% | 0.00% |
PETS | 20.51% | $95.88M | -38.46% | 0.00% |
CRBG | 20.41% | $17.90B | +52.69% | 2.90% |
SEMR | 20.23% | $2.17B | +50.31% | 0.00% |
IMKTA | 20.08% | $1.31B | -13.44% | 0.93% |
PSFE | 19.79% | $1.06B | +52.84% | 0.00% |
JJSF | 19.52% | $3.26B | -0.22% | 1.77% |
BWIN | 19.49% | $3.16B | +153.63% | 0.00% |
GSL | 19.26% | $805.69M | +29.03% | 6.74% |
AMRC | 18.98% | $1.37B | -8.95% | 0.00% |
GEL | 18.88% | $1.42B | +0.17% | 5.35% |
ONON | 18.86% | $17.99B | +103.73% | 0.00% |
RDWR | 18.39% | $968.62M | +53.31% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RITM | <0.01% | $5.61B | +5.89% | 9.22% |
FRT | -<0.01% | $9.72B | +24.23% | 3.82% |
INSM | -<0.01% | $13.20B | +211.04% | 0.00% |
SF | -0.02% | $11.77B | +86.13% | 1.41% |
PNR | 0.03% | $17.52B | +69.08% | 0.87% |
NVEE | 0.04% | $1.42B | -11.46% | 0.00% |
TBPH | -0.04% | $472.57M | -7.33% | 0.00% |
MODV | -0.04% | $249.54M | -54.73% | 0.00% |
ONIT | 0.04% | $242.27M | +15.32% | 0.00% |
FR | 0.04% | $6.97B | +15.62% | 2.70% |
MTRN | 0.05% | $2.34B | -0.48% | 0.47% |
LH | 0.05% | $20.09B | +13.50% | 0.90% |
CX | -0.05% | $8.24B | -19.38% | 0.00% |
KOD | 0.05% | $310.48M | +145.83% | 0.00% |
SMLR | 0.06% | $482.70M | +79.83% | 0.00% |
CENT | 0.06% | $2.59B | +23.89% | 0.00% |
CGBD | 0.07% | - | - | 9.42% |
VZIO | 0.07% | $2.29B | +66.81% | 0.00% |
NINE | 0.07% | $53.38M | -37.31% | 0.00% |
LITE | -0.07% | $5.88B | +96.53% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TEM | -23.61% | $8.26B | 0.00% | 0.00% |
MASI | -17.39% | $9.05B | +82.56% | 0.00% |
DV | -16.62% | $3.38B | -37.30% | 0.00% |
IRON | -15.22% | $1.89B | +22.13% | 0.00% |
TMCI | -14.48% | $494.64M | -8.00% | 0.00% |
ADBE | -12.74% | $222.05B | -18.60% | 0.00% |
JELD | -12.03% | $887.66M | -33.44% | 0.00% |
KVYO | -11.94% | $9.87B | +32.11% | 0.00% |
RYAAY | -11.90% | $23.43B | -8.79% | 0.00% |
LTM | -11.78% | $8.37B | -100.00% | <0.01% |
MLM | -11.66% | $36.10B | +27.61% | 0.51% |
CPRT | -11.48% | $54.82B | +11.81% | 0.00% |
BBU.UN | -11.32% | $1.83B | +59.60% | 1.00% |
VHC | -10.92% | $18.68M | -40.78% | 0.00% |
BLDR | -10.84% | $20.24B | +31.79% | 0.00% |
TGLS | -10.79% | $3.66B | +125.92% | 0.54% |
CVLT | -10.58% | $7.46B | +142.35% | 0.00% |
NOW | -10.26% | $215.69B | +56.36% | 0.00% |
DFH | -9.94% | $2.86B | +24.08% | 0.00% |
MCS | -9.93% | $671.70M | +50.17% | 1.30% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
EFAA | 25.60% | $116.17M | 0% |
FLRT | 17.95% | $403.38M | 0.6% |
XRT | 15.19% | $399.75M | 0.35% |
WOOD | 14.84% | $171.90M | 0.41% |
PBW | 14.69% | $297.98M | 0.65% |
RSPA | 14.45% | $272.75M | 0% |
XPH | 14.38% | $161.72M | 0.35% |
PAWZ | 14.28% | $64.96M | 0.5% |
FTXG | 14.23% | $31.13M | 0.6% |
GNOM | 14.13% | $71.22M | 0.5% |
QQA | 13.87% | $135.25M | 0% |
IHE | 13.81% | $596.24M | 0.39% |
FSTA | 13.79% | $1.20B | 0.084% |
XLP | 13.74% | $16.04B | 0.09% |
XSVM | 13.72% | $843.94M | 0.37% |
VDC | 13.65% | $7.06B | 0.1% |
YOLO | 13.60% | $34.03M | 1.03% |
BSVO | 13.46% | $1.53B | 0.47% |
FTRI | 13.45% | $124.35M | 0.7% |
EES | 13.34% | $669.12M | 0.38% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
HIGH | -0.01% | $301.36M | 0.51% |
IBDT | 0.01% | $2.37B | 0.1% |
FLDR | 0.02% | $604.50M | 0.15% |
DBJP | -0.05% | $400.73M | 0.45% |
BSCV | -0.07% | $674.62M | 0.1% |
MNA | -0.08% | $220.86M | 0.77% |
NFLT | 0.09% | $198.56M | 0.5% |
AGZD | 0.09% | $142.85M | 0.23% |
PFLD | -0.09% | $457.12M | 0.46% |
IBDS | 0.11% | $2.64B | 0.1% |
RWX | -0.13% | $251.83M | 0.59% |
PAVE | -0.13% | $9.25B | 0.47% |
USDU | -0.15% | $201.83M | 0.5% |
PDP | 0.16% | $1.39B | 0.62% |
DRSK | -0.17% | $989.23M | 0.78% |
SPTS | -0.20% | $5.70B | 0.03% |
SOXX | 0.20% | $13.67B | 0.35% |
SOXQ | -0.21% | $478.59M | 0.19% |
SRVR | 0.22% | $443.64M | 0.55% |
NUAG | -0.23% | $37.56M | 0.21% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ULST | -12.65% | $535.66M | 0.2% |
IBTE | -11.41% | $1.67B | 0.07% |
VIXY | -9.74% | $195.31M | 0.85% |
IBD | -8.84% | $330.68M | 0.44% |
PGX | -8.45% | $4.36B | 0.5% |
YEAR | -8.29% | $1.14B | 0.25% |
PWZ | -8.18% | $697.13M | 0.28% |
SHV | -7.85% | $18.36B | 0.15% |
JBBB | -7.68% | $1.27B | 0.49% |
DUSB | -7.50% | $812.64M | 0.15% |
GBIL | -7.44% | $5.64B | 0.12% |
CTA | -7.38% | $359.48M | 0.78% |
IBTF | -7.21% | $2.07B | 0.07% |
EQLS | -6.85% | $8.88M | 1% |
IBMM | -6.43% | $360.11M | 0.18% |
AGZ | -6.43% | $709.69M | 0.2% |
STPZ | -6.18% | $483.68M | 0.2% |
PFFR | -6.16% | $110.83M | 0.45% |
PSK | -6.07% | $910.73M | 0.45% |
LQDW | -6.01% | $207.27M | 0.34% |
Yahoo
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission ...
Yahoo
SHELTON, Conn. AP) — NanoViricides Inc. NNVC) on Thursday reported a loss of $3.1 million in its fiscal first quarter.
Yahoo
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and ...
Yahoo
SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and ...
Yahoo
SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and ...
Yahoo
We recently compiled a list of the 7 Best Nanotech Penny Stocks to Buy. In this article, we are going to take a look at where NanoViricides Inc. (NYSE:NNVC) stands against the other the Best Nanotech Penny Stock to Buy. Market Outlook and Investment Opportunities The Federal Reserve’s recent half-point rate cut is expected to benefit small-cap […]
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.